31-Mar-2026
No headlines found.
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 26-Mar 4:05 PM ET)
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
Iridex Announces Plans to Relocate Headquarters
Globe Newswire (Mon, 2-Feb 7:00 AM ET)
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
Globe Newswire (Mon, 12-Jan 7:00 AM ET)
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Iridex trades on the NASDAQ stock market under the symbol IRIX.
As of March 31, 2026, IRIX stock price climbed to $1.01 with 89,733 million shares trading.
IRIX has a beta of 1.23, meaning it tends to be more sensitive to market movements. IRIX has a correlation of 0.08 to the broad based SPY ETF.
IRIX has a market cap of $17.36 million. This is considered a Sub-Micro Cap stock.
Last quarter Iridex reported $15 million in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-16,000 and exceeded earnings estimates by $.01.
In the last 3 years, IRIX traded as high as $3.65 and as low as $.78.
The top ETF exchange traded funds that IRIX belongs to (by Net Assets): VTI, VXF.
IRIX has underperformed the market in the last year with a price return of +2.0% while the SPY ETF gained +17.6%. IRIX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.4% and -24.1%, respectively, while the SPY returned -4.4% and -2.8%, respectively.
IRIX support price is $.94 and resistance is $1.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRIX shares will trade within this expected range on the day.